Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and…

Krakow, Poland – 16 May 2019 – Selvita today announced that abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for poster presentations at the 2019 American Society of Clinical Oncology (ASCO) annual meeting and 24th Annual European Hematology Association (EHA) Congress are now available online. The poster entitled “CLI24-001: First-in-human…

More

Selvita to Present at the UBS 2019 Global Healthcare Conference in New York

Krakow, Poland – 13 May 2019 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that the company will present at the UBS Global Healthcare Conference, taking place on May 20-22 in New York. Chief Executive…

More

Selvita appoints Tom Coulter as Integrated Drug Discovery Director

Krakow, Poland – 09 May 2019 – Selvita, one of the largest providers of drug discovery services in Europe, announced today the appointment of Tom Coulter, to the role of Integrated Drug Discovery Director. Dr. Coulter has joined Selvita in May and will be responsible for the scientific progress and…

More

Selvita to exhibit at the 14th Annual Drug Discovery Chemistry conference

Krakow, Poland – 4 April 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, will exhibit at the upcoming 14th Annual Drug Discovery Chemistry conference, taking place 8-12 April at the San Diego Convention Center, in San Diego, US.   Throughout the whole event, Selvita’s…

More

123